Age 0 3 0 3 B-age
greater 4 11 4 11 O
than 12 16 12 16 O
or 17 19 17 19 O
equal 20 25 20 25 O
to 26 28 26 28 O
( 29 30 29 30 O
> 30 31 30 31 O
/= 31 33 31 33 O
) 33 34 33 34 O
18 35 37 35 37 B-lower_bound
years 38 43 38 43 I-lower_bound

Agreement 0 9 44 53 B-contraception_consent
to 10 12 54 56 I-contraception_consent
remain 13 19 57 63 I-contraception_consent
abstinent 20 29 64 73 I-contraception_consent
or 30 32 74 76 O
use 33 36 77 80 B-contraception_consent
adequate 37 45 81 89 I-contraception_consent
contraception 46 59 90 103 I-contraception_consent
, 59 60 103 104 O
among 61 66 105 110 O
women 67 72 111 116 B-gender
or 73 75 117 119 I-gender
men 76 79 120 123 I-gender
of 80 82 124 126 O
childbearing 83 95 127 139 O
potential 96 105 140 149 O

Current 0 7 150 157 O
use 8 11 158 161 O
of 12 14 162 164 O
systemic 15 23 165 173 B-treatment
immunosuppressant(s 24 43 174 193 I-treatment
) 43 44 193 194 I-treatment
, 44 45 194 195 O
or 46 48 196 198 O
prior 49 54 199 204 B-treatment
anti 55 59 205 209 I-treatment
- 59 60 209 210 I-treatment
cancer 60 66 210 216 I-treatment
therapy 67 74 217 224 I-treatment
to 75 77 225 227 O
include 78 85 228 235 O
: 85 86 235 236 O
lenalidomide 87 99 237 249 B-treatment
, 99 100 249 250 O
fludarabine 101 112 251 262 B-treatment
, 112 113 262 263 O
or 114 116 264 266 O
alemtuzumab 117 128 267 278 B-treatment
within 129 135 279 285 O
12 136 138 286 288 B-upper_bound
months 139 145 289 295 I-upper_bound
; 145 146 295 296 O
radioimmunoconjugate 147 167 297 317 B-treatment
within 168 174 318 324 O
12 175 177 325 327 B-upper_bound
weeks 178 183 328 333 I-upper_bound
; 183 184 333 334 O
mAb 185 188 335 338 B-treatment
or 189 191 339 341 O
antibody 192 200 342 350 B-treatment
- 200 201 350 351 I-treatment
drug 201 205 351 355 I-treatment
conjugate 206 215 356 365 I-treatment
within 216 222 366 372 O
4 223 224 373 374 B-upper_bound
weeks 225 230 375 380 I-upper_bound
; 230 231 380 381 O
or 232 234 382 384 O
radiotherapy 235 247 385 397 B-treatment
/ 247 248 397 398 O
chemotherapy 248 260 398 410 B-treatment
/ 260 261 410 411 O
hormone 261 268 411 418 B-treatment
therapy 269 276 419 426 I-treatment
/ 276 277 426 427 O
targeted 277 285 427 435 B-treatment
small 286 291 436 441 I-treatment
- 291 292 441 442 I-treatment
molecule 292 300 442 450 I-treatment
therapy 301 308 451 458 I-treatment
within 309 315 459 465 O
2 316 317 466 467 B-upper_bound
weeks 318 323 468 473 I-upper_bound
prior 324 329 474 479 I-upper_bound
to 330 332 480 482 O
Day 333 336 483 486 O
1 337 338 487 488 O
of 339 341 489 491 O
Cycle 342 347 492 497 O
1 348 349 498 499 O

For 0 3 500 503 O
obinutuzumab 4 16 504 516 B-treatment
in 17 19 517 519 O
combination 20 31 520 531 O
with 32 36 532 536 O
polatuzumab 37 48 537 548 B-treatment
vedotin 49 56 549 556 I-treatment
and 57 60 557 560 O
lenalidomide 61 73 561 573 B-treatment
( 74 75 574 575 I-treatment
G 75 76 575 576 I-treatment
+ 77 78 577 578 I-treatment
Pola 79 83 579 583 I-treatment
+ 84 85 584 585 I-treatment
Len 86 89 586 589 I-treatment
) 89 90 589 590 I-treatment
treatment 91 100 591 600 I-treatment
group 101 106 601 606 O
: 106 107 606 607 O
R 108 109 608 609 O
/ 109 110 609 610 O
R 110 111 610 611 O
FL 112 114 612 614 O
after 115 120 615 620 O
treatment 121 130 621 630 O
with 131 135 631 635 O
at 136 138 636 638 O
least 139 144 639 644 O
one 145 148 645 648 O
prior 149 154 649 654 O
chemoimmunotherapy 155 173 655 673 B-treatment
regimen 174 181 674 681 O
that 182 186 682 686 O
included 187 195 687 695 O
an 196 198 696 698 O
anti 199 203 699 703 O
- 203 204 703 704 O
CD20 204 208 704 708 O
monoclonal 209 219 709 719 O
antibody 220 228 720 728 O
and 229 232 729 732 O
for 233 236 733 736 O
which 237 242 737 742 O
no 243 245 743 745 O
other 246 251 746 751 O
more 252 256 752 756 O
appropriate 257 268 757 768 O
treatment 269 278 769 778 O
option 279 285 779 785 O
exists 286 292 786 792 O
as 293 295 793 795 O
determined 296 306 796 806 O
by 307 309 807 809 O
the 310 313 810 813 O
investigator 314 326 814 826 O

For 0 3 827 830 O
rituximab 4 13 831 840 B-treatment
in 14 16 841 843 O
combination 17 28 844 855 O
with 29 33 856 860 O
polatuzumab 34 45 861 872 B-treatment
vedotin 46 53 873 880 I-treatment
and 54 57 881 884 O
lenalidomide 58 70 885 897 B-treatment
( 71 72 898 899 O
R 72 73 899 900 O
+ 74 75 901 902 O
Pola 76 80 903 907 O
+ 81 82 908 909 O
Len 83 86 910 913 O
) 86 87 913 914 O
treatment 88 97 915 924 O
group 98 103 925 930 O
: 103 104 930 931 O
R 105 106 932 933 O
/ 106 107 933 934 O
R 107 108 934 935 O
DLBCL 109 114 936 941 B-cancer
after 115 120 942 947 O
treatment 121 130 948 957 O
with 131 135 958 962 O
at 136 138 963 965 O
least 139 144 966 971 O
one 145 148 972 975 B-lower_bound
prior 149 154 976 981 B-treatment
chemoimmunotherapy 155 173 982 1000 I-treatment
regimen 174 181 1001 1008 O
that 182 186 1009 1013 O
included 187 195 1014 1022 O
an 196 198 1023 1025 O
anti 199 203 1026 1030 B-treatment
- 203 204 1030 1031 I-treatment
CD20 204 208 1031 1035 I-treatment
monoclonal 209 219 1036 1046 I-treatment
antibody 220 228 1047 1055 I-treatment
in 229 231 1056 1058 O
patients 232 240 1059 1067 O
who 241 244 1068 1071 O
are 245 248 1072 1075 O
not 249 252 1076 1079 O
eligible 253 261 1080 1088 O
for 262 265 1089 1092 O
autologous 266 276 1093 1103 B-treatment
stem 277 281 1104 1108 I-treatment
- 281 282 1108 1109 I-treatment
cell 282 286 1109 1113 I-treatment
transplantation 287 302 1114 1129 I-treatment
or 303 305 1130 1132 O
who 306 309 1133 1136 O
have 310 314 1137 1141 O
experienced 315 326 1142 1153 O
disease 327 334 1154 1161 O
progression 335 346 1162 1173 O
following 347 356 1174 1183 O
treatment 357 366 1184 1193 O
with 367 371 1194 1198 O
high 372 376 1199 1203 O
- 376 377 1203 1204 O
dose 377 381 1204 1208 O
chemotherapy 382 394 1209 1221 B-treatment
plus 395 399 1222 1226 O
autologous 400 410 1227 1237 O
stem 411 415 1238 1242 O
- 415 416 1242 1243 O
cell 416 420 1243 1247 O
transplantation 421 436 1248 1263 O

Histologically 0 14 1264 1278 O
documented 15 25 1279 1289 O
CD20 26 30 1290 1294 B-clinical_variable
- 30 31 1294 1295 O
positive 31 39 1295 1303 O
B 40 41 1304 1305 B-cancer
- 41 42 1305 1306 I-cancer
cell 42 46 1306 1310 I-cancer
lymphoma 47 55 1311 1319 I-cancer
as 56 58 1320 1322 O
determined 59 69 1323 1333 O
by 70 72 1334 1336 O
the 73 76 1337 1340 O
local 77 82 1341 1346 O
laboratory 83 93 1347 1357 O

Life 0 4 1358 1362 B-clinical_variable
expectancy 5 15 1363 1373 I-clinical_variable
less 16 20 1374 1378 O
than 21 25 1379 1383 O
( 26 27 1384 1385 O
< 27 28 1385 1386 O
) 28 29 1386 1387 O
3 30 31 1388 1389 B-upper_bound
months 32 38 1390 1396 I-upper_bound

Poor 0 4 1397 1401 O
hematologic 5 16 1402 1413 B-chronic_disease
, 16 17 1413 1414 O
renal 18 23 1415 1420 B-chronic_disease
, 23 24 1420 1421 O
or 25 27 1422 1424 O
hepatic 28 35 1425 1432 B-chronic_disease
function 36 44 1433 1441 I-chronic_disease

Positive 0 8 1442 1450 O
for 9 12 1451 1454 O
human 13 18 1455 1460 B-chronic_disease
immunodeficiency 19 35 1461 1477 I-chronic_disease
virus 36 41 1478 1483 I-chronic_disease
( 42 43 1484 1485 I-chronic_disease
HIV 43 46 1485 1488 I-chronic_disease
) 46 47 1488 1489 I-chronic_disease
or 48 50 1490 1492 O
hepatitis 51 60 1493 1502 B-chronic_disease
B 61 62 1503 1504 I-chronic_disease
or 63 65 1505 1507 I-chronic_disease
C 66 67 1508 1509 I-chronic_disease

Pregnant 0 8 1510 1518 B-pregnancy

fluorodeoxyglucose 0 18 1519 1537 B-treatment
( 19 20 1538 1539 I-treatment
FDG)-avid 20 29 1539 1548 I-treatment
lymphoma 30 38 1549 1557 B-cancer
( 39 40 1558 1559 O
i.e. 40 44 1559 1563 O
, 44 45 1563 1564 O
positron 46 54 1565 1573 B-treatment
emission 55 63 1574 1582 I-treatment
tomography 64 74 1583 1593 I-treatment
( 75 76 1594 1595 I-treatment
PET)-positive 76 89 1595 1608 I-treatment
lymphoma 90 98 1609 1617 O
) 98 99 1617 1618 O

lactating 0 9 1619 1628 O
women 10 15 1629 1634 B-gender

